Hypertriglyceridaemia and reduced HDL-cholesterol concentrations are the prominent features of the atherogenic dyslipaemia commonly observed in insulin-resistance states [1, 2] and Type II (non-insulin-dependent) diabetes mellitus [3±6]. Severe hypertriglyceridaemia is not uncommon in Type II diabetes [7, 8] but its prevalence and mechanism are not clearly established. Mild hypertriglyceridaemia in Type II diabetes is dependent upon glucose control and nutritional factors such as intake of carbohydrates and alcohol. Genetic factors might, however, determine individual susceptibility to major hypertriglyceridaemia. Although VLDL hepatic overproduction is well documented in Type II diabetes, genetic defect in the clearance of the triglyceride-rich Diabetologia (2000) Abstract Aims/hypothesis. Hypertriglyceridaemia is common in Type II (non-insulin-dependent) diabetes mellitus. Only subgroups of patient however have type V hyperlipidaemia. To investigate the coordination between genetic factors in the modulation of hypertriglyceridaemia in Type II diabetes, we studied three major modifier loci: apoC-III (both Sst-I and insulinresponsive element polymorphisms), apolipoprotein E genotypes and lipoprotein-lipase mutations. Methods. We studied apoCIII gene polymorphisms, apolipoprotein E genotypes and lipoprotein-lipase gene mutations in 176 patients with Type II (non-insulin-dependent) diabetes mellitus, either normolipaemic (group N, n = 116), mildly hypertriglyceridaemic (group T, n = 28) or with a history of severe hypertriglyceridaemia (triglyceride > 15 g/l) (group H, n = 32). Results. Mild hypertriglyceridaemia in Type II diabetes did not associate with any gene variants in this study. Severe hypertriglyceridaemia was, however, associated with the presence of the apoC-III S2 allele (50 % of the patients in group H compared with 15.5 % in group N, p < 0.0001). Additionally this particular phenotype was associated with a low prevalence of the apo E3 allele (35.9 % in group H vs 18.1 % in group N, p < 0.005) and a statistically significant over-representation of the E2E4 genotypes. Inactivating lipoprotein-lipase mutations were found in four patients (three heterozygotes, one homozygote), none was found in group N or T. Thus 68.7 % of group H patients (22/32) (vs 21.4 % in group T, p < 0.0005) were carriers of either S2 allele, lipoprotein-lipase mutants or E2E4 genotype with most lipoprotein-lipase mutants or E2E4 genotypes or both in the non-carriers for the S2 allele (6/7). Conclusion/interpretation. Our results strongly support the hypothesis that severe hyperlipaemia in Type II diabetes crucially depends on genetic factors which impair the clearance of triglyceride-rich lipoproteins.
lipoproteins could further modulate the expression of dyslipaemia.
As individual factors, heterozygote lipoprotein lipase (LPL) deficiency and carrier status for apo E2 and/or E4 variants have been suggested to be determinants of genetic susceptibility to dyslipaemia in Type II diabetes [7, 8, 9] . Additionnally apoC-III is a major modulator of triglyceride concentrations through a down-regulation of LPL activity and triglyceride-rich lipoprotein clearance, as shown by studies in transgenic and knockout models [10, 11] . The gene cluster polymorphisms apo AI-CIII-AIV were associated with hypertriglyceridaemia and coronary heart disease in population studies [12] . The most consistent associations were reported for the S2 variant (RFLP-Sst-I + ) in apoC-III exon 4 (C3238G) [13±18] . Moreover this polymorphism has a modifier effect on familial combined hyperlipidaemia [19, 20] and type III hyperlipoproteinaemia [21] . No study has, however, been conducted in diabetic dyslipaemia. Additionnally two apoC-III promotor polymorphisms (T-455C and C-482T) were shown to inactivate a negative insulin-responsive element located between nucleotide ±449 and ±490 [22] and are in linkage-disequilibrium with the apoC-III Sst-I polymorphism [17] .
We therefore undertook an association study in Type II diabetes hypertriglyceridaemia to investigate gene alterations at apoC-III, apo E and LPL loci either in combination or as alternative risk factors. We decided to study a particular subgroup of diabetic patients with a history of severe hypertriglyceridaemia considering that this particular phenotype might depend on genetic predisposition factors.
Subjects and methods
Patient assessment. The normotriglyceridaemic and mildly hypertriglyceridaemic patients were 144 consecutive Type II diabetic patients (35±73 years old, 49 women, 95 men) with at least one additional risk factor included in the DIACOR study (Table 1) aimed to test the predictive value of carotid intima thickness for cardiovascular events. Exclusion criteria were: ketonuria, fasting glycaemia above 15 mmol/l, insulin therapy, concomitant illness (hepatic or renal insufficiency, neoplasm) history of severe hypertriglyceridaemia and heavy alcohol consumption ( > 40 g/day). The 119 patients of group N were normolipaemic at the moment of inclusion with triglyceride or total cholesterol plasma concentrations below the 90th centile after adjustment for age and sex without hypolipaemic medication. The 28 patients of group T had triglyceride plasma concentrations above the 90th centile after adjustment for age and sex, the highest triglyceride concentration in this group was 4.9 mmol/l and none of the patients from group T were receiving hypolipaemic agents. The 32 group H patients (Table 1) all fulfilled the criteria of Type II diabetes without ketosis, were obese (BMI > 25) and over 40 years old. Patients were included in group H when they had a documented history of transient episodes of severe fasting hypertriglyceridaemia with plasma triglyceride concentrations over 15 mmol/l and with a triglyceride to total cholesterol ratio above 2.5 (in g/l). They were consecutive patients referred to our university hospital lipid clinics for uncontrolled severe hypertriglyceridaemia and therefore did not originate from the DIACOR cohort. A plasma triglyceride concentration cut-off of 15 mmol/l was selected because it was established that this concentration corresponds with the occurrence of hyperchylomicronaemia [23] which was confirmed in the subjects who still had triglyceride concentrations above 15 mmol/l when referred to our lipid clinic (11/32) . Due to the severity of hypertriglyceridaemia, some of the group H patients were treated with insulin (15/32) or fibrates (18/32) to restore plasma triglyceride concentrations to normal. This group was therefore excluded from the analysis of genotype effects on lipid variables. A registered dietetician recorded the diet of all the patients. The study protocol accorded with the requirements of the local ethics committees and written informed consent was obtained from all the patients included in the study.
Biological variables. Blood samples were obtained in the fasting state and drawn on EDTA. Triglyceride and total cholesterol plasma concentrations were measured enzymatically. Apolipoprotein B was measured by ELISA. High density lipoprotein cholesterol (HDLc) and low density lipoprotein cholesterol (LDLc) were measured after ultracentrifugation of triglyceride-rich lipoproteins when plasma triglyceride concentrations were over 4.5 mmol/l. The HbA 1 c values were measured by HPLC analysis.
Analysis of apoC-III Sst-I and apoC-III IRE DNA polymorphism. We analysed the Sst-I RFLP at nucleotide 3238 of apoC-III locus in all patients as reported previously [24] . The alleles for the apoC-III ±455T/C and ±482C/T polymorphisms were determined in all patients. For this purpose, a 146 bp PCR products (from nucleotide ±421 to ±525) encompassing the apoC-III IRE were prepared with the following primers: AC3P1 (5'-GAGGTGCTGGAAGGGGCTGTGA-3') and AC3P2 (5'-GAGGGGTGAGGGACTTCTTC-3'). Polymerase chain reaction mix was done with Taq polymerase and buffer (Appligene, Oncor, Illkirch, France), deoxyribonucleotide triphosphate (dNTP) (100 mmol/l), primers (100 nmol/l each), DMSO (3 %). After 5 min of initial denaturation at 94 C, 35 cycles of 40 s at 94 C, 1 min at 58 C, 40 s at 72 C were carried out followed by 10 min of primer extention at 72 C. Two methods were systematically carried out. The nucleotides at position ±455 and ±482 positions were determined using an allele-specific oligonucleotide hybridization as described previously [17] . A single strand conformational polymorphism (SSCP) analysis was done to investigate the presence of unreported apoC-III IRE sequence variations in Type II diabetes. For SSCP analysis, PCR of the apoC-III IRE sequence was modified as follows: dNTP were 5 mmol/l and 10 mCi dATPa 33 P was added ( > 93 TBq/mmol). The SSCP analysis of 33 P labelled PCR products was carried out using non-denaturing electrophoresis in 12 % polyacrylamide (37:1) gels under two conditions: at 4 C with 10 % glycerol and at 20 C without glycerol.
LPL gene mutation screening and apo E genotyping. In all patients of groups T and H, PCR products for SSCP analysis of LPL were prepared as reported previously for exon 1 to 9 [25, 26] and for the proximal promoter sequences (NT ±103 to + 45) [27] . The SSCP analysis was carried out according to two methods of electrophoresis as described for the apoC-III IRE. The DNA sequencing was done with both forward and reverse primers using the Thermosequenase kit (USB, Amersham Life science, Cleveland, Ohio, USA) according to the manufacturer's instructions. Apolipoprotein E genotypes were determined as reported previously [28] .
Statistical methods. Differences between groups of patients for allele and genotype frequencies were tested using either the chi-squared or the Fisher's exact test when appropriate. Differences between groups for the mean values of quantitative measurements were tested using ANOVA or non-parametric analysis (Mann-Whitney or Kruskall-Wallis tests) when appropriate. Differences between groups and/or genotypes were considered as significant when the p value was less than 0.05.
Results
In all patients (group N, T and H), only the four reported haplotypes corresponding to a combination of NT ±455C/T and ±482T/C polymorphisms were found by systematic SSCP screening for mutations of apoC-III proximal promoter (NT ±421 to ±525). In the Type II diabetic patients without a history of severe hypertriglyceridaemia, the prevalence of alleles or genotypes for C3Sst-I RFLP, apoC-III IRE polymorphisms and apo E were similar in the normolipaemic (group N) or mildly hypertriglyceridaemic (group T) patients (Table 2 and 3) . In these subjects (N and/or T) none of the genotypes at C3Sst-I, apoC-III IRE or apo E loci showed a statistically significant association with fasting concentrations of triglyceride, total cholesterol, HDLc, LDLc or apoB (data not shown). The genotype distributions for apoC-III IRE, Sst-I and apo E polymorphisms were in the Hardy-Weinberg equilibrium.
Among the patients with Type II diabetes and a history of severe hypertriglyceridaemia (group H) the C3Sst-I S2 allele was over threefold as frequent as in group N (p < 0.0001) or group T (p < 0.005). In group H, 50 % of the patients were carriers of the S2 allele in contrast with only 15.5 % in group N (p < 0.0001) and 17.9 % in group T (p < 0.01). Both heterozygotes and homozygotes carriers of S2 allele were statistically significantly over-represented compared with subjects without a history of severe hypertriglyceridaemia (Table 2 ). In contrast, for the ±455 and ±482 nucleotide polymorphisms, the allele and genotype frequencies were similar in the three groups of patients (Table 2) .
In group H compared with either group N or N + T, the frequency of the common apo E3 allele was reduced (p < 0.005) and the E2E4 genotype was over-represented (p < 0.005) ( Table 3) . Because apoC-III S2 polymorphism was highly over-represented in group H, we considered the status of apo E locus separately in S2 carriers and non-carriers. The statistically significant decrease in apo E3 allele frequency and the increase in apo E2E4 genotype frequency were found only among the subjects with the S1S1 genotype (allele E3: 59.4 % in group H vs 81.0 % in group N + T, p = 0.005 and E2E4 genotype: 25.0 % in group H vs 1.0 % in group N + T, p < 0.005). In contrast the E2E4 genotype was uncommon among the S2 carriers of both group H (1/16 patients) and N + T (1/121 patients).
Results of LPL gene mutation screening in the 60 hypertriglyceridaemic patients with mild hypertriglyceridaemia or history of severe hypertriglyceridaemia are summarized in Table 4 . Inactivating nonsense or missense LPL mutations were observed only in group H. One patient was homozygote for the CGA192TGA (R192X) mutant. This patient had the apo E3E3 and apoC-III Sst-I S1S1 genotypes. Three out of 32 patients were heterozygotes (9.3 %), two for the GAG188GGG mutant (G188E) and one for the AAG147TAG mutant (K147X). In contrast, common LPL gene coding polymorphisms at codon 9, 291 and 447 were found at similar frequencies in group T as in group H (Table 4) . In group H, patients with either LPL mutants or E2E4 genotypes or both tended to cluster in the subgroup with the S1S1 genotype (6/7). Overall a genetic alteration in either loci was found in the majority of the diabetic patients with a history of severe hypertriglyceridaemia: 22 out of 32 patients (68.7 %) were carriers of either apoC-III S2 allele, LPL mutants or E2E4 genotype, in contrast to only 6 out of 28 in group T (21.4 %, p < 0.0005) (Fig. 1 ).
Discussion
Our study of a large group of Type II diabetic patients with a history of severe hypertriglyceridaemia led us to uncover a critical influence of three loci involved in the regulation of triglyceride-rich lipoprotein clearance: apoC-III (S2 polymorphism), apo E (E3 allele deficiency) and LPL gene mutations. Among Type II diabetic subjects without a history of type-V hyperlipidaemia, the influence of these genetic variants on plasma lipid parameters was, however, insufficient to be detected in our study. Patients with a history of severe hypertriglyceridaemia had a 1.3 % increase in HbA 1 c value compared with the two other groups. Such a mild impairment in glycaemic control is expected to account for only a moderate increase of triglyceride plasma concentration [29] . It was reported that severe hypertriglyceridaemia in Type II diabetes occurs in only a minority of patients with an additional familial predisposition to dyslipaemia [9, 30] . We found a strong association between the occurrence of severe hypertriglyceridaemia and the carrier status for apoC-III Sst-I polymorphism (S2 allele) in Type II diabetes. In non-selected population studies the S2 variant was consistently associated with hypertriglyceridaemia [12] and with higher plasma concentrations of apoC-III [18, 31] , a key modulator of plasma triglyceride clearance which can cause hypertriglyceridaemia when over-expressed [10, 11] . Additionally, the presence of an S2-associated apoC-III allele is a dominant risk factor for familial forms of dyslipaemia such as familial combined hyperlipidaemia [20, 32] or type III hyperlipoproteinaemia [21] . Furthermore among apo E2 homozygotes the presence of the S2 allele has recently been reported to be strongly associated with severe hypertriglyceridaemia exclusively in the subjects with hyperinsulinaemia although not in the overall study [21] . Our results from type II diabetic patients indicate that an S2-linked genetic alteration could have a modifier effect on diabetic dyslipaemia and thus provides further confirmation of the hypothesis of an interaction between insulin resistance and the apoC-III S2 allele.
Although discovered in 1983 [13, 14] , the association between the S2 allele and hypertriglyceridaemia has not been explained. The S2 mutation locates in a non-coding region of apoC-III exon 4 and thus does not alter a known functional domain. It was recently suggested that the association of S2 with increased triglyceride concentrations is related to an enhanced allele-specific expression of the apoC-III transcripts bearing the S2 variant compared with the S1-linked allele [33] . This could result from a linkage to a mutation in promotor sequences regulating apoC-III transcription. The T-455C and C-482T variants in the apoC-III promoter insulin-responsive element (IRE) were shown to associate with hypertriglyceridaemia in non-diabetic subjects [25] but subsequent studies clearly established this to be related to linkage-disequilibrium with the S2 allele [12] . An involvement of IRE polymorphisms in diabetic dyslipaemia was, however, not ruled out because both IRE variants induce an insulin-responsiveness defect [22] and insulin was shown to down-regulate the transcription of apoC-III gene both in the human hepatoma hepG2 cell line and in a rodent diabetes model [34] . Our mutation-screening of apoC-III IRE only found the previously reported T-455C and C-482T polymorphisms and neither statistically significantly influenced plasma triglyceride concentration nor were they associated with the occurrence of mild or severe dyslipaemia. Our data, overall, indicates that a contribution of genetic alterations in the apoC-III IRE to mild or to severe hypertriglyceridaemia in Type II diabetes is, in contrast to Sst1 polymorphism, unlikely.
Heterozygote LPL deficiency has been shown to be a risk factor for severe dyslipaemia in non-diabetic subjects [25, 35, 36] and could, together with age-related influences, account for the occurrence of a familial form of hypertriglyceridaemia [37±39]. Furthermore, insulin resistance was suggested to be a determinant of the occurrence of hypertriglyceridaemia in heterozygous LPL deficiency [9, 40, 41] . We did not, however, detect LPL gene alterations in patients with mild hypertriglyceridaemia, in agreement with a previous study of diabetic and hypertriglyceridaemic members of Type II diabetic families [42] . In Type II diabetes with severe hypertriglyceridaemia, LPL gene mutations were reported either in isolated cases [9] or in a small group of patients [43] . Lipoprotein lipase activity in plasma after heparin treatment and in adipose tissue is decreased in hypertriglyceridaemic Type II diabetic patients and in insulin-resistant obese subjects [30, 44] . Therefore, heterozygote genetic impairment could further reduce the functional lipoprotein lipase activity and lead to severe hypertriglyceridaemia. We found, however, only 4 patients with LPL gene mutations in our larger group of 32 subjects with severe hypertriglyceridaemia. The mutant alleles detected in our study were either previously documented as defective (G188E) [26] or were nonsense (K147X and R192X) predicting severe lipoprotein lipase function defects [45] . Deficiency of LPL is likely to account, however, only for a minority of the severe hypertriglyceridaemic states in Type II diabetic patients (only 12.5 % in our study).
Both E2 and E4 alleles are over-represented in non-diabetic patients with severe hypertriglyceridaemia [46, 47] . In Type II diabetes, only two studies of small groups (n < 10) of patients with severe hyper- [7, 8] . We confirm and extend these observations: we report an over-representation of the E2E4 genotype in severe hypertriglyceridaemia. This rare apo E genotype could therefore determine a particular risk for severe dyslipaemia, at least in Type II diabetes. It was established in 1989 that E2 allele is a determinant of triglyceride concentrations in Type II diabetes [48] as in non-diabetic subjects [49] . The E4 allele was also associated with increased fasting triglyceride concentrations [49, 50] and considered as a statistically significant determinant of the postprandial response of triglycerides in population studies [51, 52] . Furthermore in Type II diabetic patients without fasting hyperlipaemia the carrier status for either E2 or E4 or both was a determinant of delayed and increased postprandial lipaemia [53] . An enhanced risk for hyperlipoproteinaemia when E2 or E4 variants or both are expressed could therefore account for the low prevalence of the E3 allele that we observed in our group of Type II diabetic patients with severe hypertriglyceridaemia.
Our data, overall, suggests that S2 or IRE-linked apoC-III gene alteration, LPL mutations or apo E3 deficiency do not play a major part in the occurrence of mild hypertriglyceridaemia in Type II diabetes when subjects with a history of severe hypertriglyceridaemia are excluded. It was earlier suggested that most Type II diabetic patients with severe hyperlipaemia have an independent familial form of hypertriglyceridaemia [30] . We found an association between severe hypertriglyceridaemia in Type II diabetes and variants at three loci crucial for the control of triglyceride-rich lipoprotein clearance, in nearly 70 % of the patients. In these subjects, the most frequent variant was the apoC-III S2 polymorphism, present in half of the patients. Notably the E2E4 and LPL mutation carriers tended to cluster in the subgroup of patients without the S2 allele. This finding needs to be considered with caution because of the small number of patients in the subgroups. Our results strongly suggest that the predisposition to severe hypertriglyceridaemia in Type II diabetes frequently requires, at least as co-factors, alterations at genetic loci crucially involved in the control of triglyceride-rich lipoprotein clearance and associated with plasma triglycerides variability in population studies. No relevant association was observed in about one third of these patients; thus other alterations at apoC-III, LPL, or apo E loci as well as at additional genetic loci could be involved.
